Blinatumomab for Relapsed Acute B Lymphoblastic Leukemia After Transplantation

B-ALL patients received regular follow-up after allogeneic hematopoietic stem cell transplantation, and in case of recurrence, they were given Blinatumomab. Anti-treatment was followed by DLI, and the second course was performed 1-2 months after DLI. Patients with positive MRD were treated with Blinatumomab 28μg×5-15 days, followed by DLI treatment. (MNC infusion is about 5×10\^7/kg\~1×10\^8/kg). Patients with hematologic recurrence were given Blinatumomab 9μg D1-4,11.66μg d5-7,28μg Starting from d8 (8 to 21 days in total), followed by DLI treatment (infusion of MNC approximately 5×10\^7/kg

Trial Details

NCT ID
NCT06339775
Phase
PHASE4
Sponsor
Suping ZHANG
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • Blinatumomab
Locations (sample)
  • Zhenzhou, Henan, China

Key Eligibility Criteria

  • Age ≤65 years old
  • Stable vital signs
  • No severe infection
  • There was no grade II-IV graft-versus-host disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →